)
Visual
test
Elicio Therapeutics
Elicio Therapeutics (ELTX) investor relations material
Elicio Therapeutics Registration Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration Filing summary13 Nov, 2025
Company overview and business model
Clinical-stage biotechnology company developing immunotherapies for cancer patients with limited treatment options and poor outcomes, leveraging proprietary Amphiphile (AMP) technology to generate robust anti-tumor T cell responses by targeting lymph nodes.
Lead program ELI-002 7P targets mutant KRAS pancreatic ductal adenocarcinoma (PDAC) and is in Phase 2 clinical trials, with a favorable safety profile and final disease-free survival analysis expected in the first half of 2026.
Pipeline includes additional preclinical candidates for b-raf and p53 mutated cancers, aiming to provide off-the-shelf therapeutic options using common neoantigens.
Corporate history includes a merger with Angion Biomedica Corp in January 2023, resulting in the current structure and name.
Financial performance and metrics
Completed a $10 million Senior Secured Promissory Note financing in June 2025, with proceeds intended for working capital and general corporate purposes.
The company’s financial statements for the year ended December 31, 2024, include a going concern explanatory paragraph from its independent auditor.
Use of proceeds and capital allocation
Will not receive proceeds from the resale of shares by the selling stockholder; any proceeds from cash exercise of the warrant will be used for working capital and general corporate purposes.
Implications of IDMC's ELI-002 7P recommendation
Impact of GKCC Note Financing on cash runway
Mitigation of going concern risk
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- STC
Scalable, high-margin IT communications provider for SMBs with strong recurring revenue and growth momentum. - APAM
AUM hit $180B, strong returns and Grandview deal drove growth despite equity outflows. - GM
Disciplined transformation, resilient supply chains, and strategic EV focus drive robust results. - BTBT
Transitioned to a strategic asset model with major stakes in Ethereum and AI infrastructure. - PSX
Q4 2025 earnings hit $2.9B, with record refining yields and strong portfolio transformation. - ARCC
FY 2025 delivered $2.01 Core EPS, $1.86 net income/share, and a $0.48 Q1 2026 dividend. - HMN
Record core earnings, 12.4% ROE, and 10% EPS growth guidance for 2026. - AFG
Record underwriting profit, strong ROE, and over $700M returned to shareholders in 2025. - OXBR
Tokenized reinsurance contracts on Solana open Florida's market to global investors. - PNDORA
2025 organic growth reached 6%, with EBIT margin at 23.9% and cautious 2026 outlook.
Next Elicio Therapeutics earnings date
Q4 202527 Mar, 2026
Elicio Therapeutics
Next Elicio Therapeutics earnings date
Q4 202527 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Elicio Therapeutics Inc. is a biotechnology company focused on developing immunotherapies for the treatment of cancer and infectious diseases. The company specializes in AMP (Amphiphile) platform technology, designed to enhance the delivery of cancer vaccines and immunomodulators to the lymphatic system, improving immune response. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage